Corvus Debt Ratio from 2010 to 2024

CRVS Stock  USD 8.94  0.70  8.50%   
Corvus Pharmaceuticals Debt Ratio yearly trend continues to be comparatively stable with very little volatility. Debt Ratio is likely to outpace its year average in 2024. From the period from 2010 to 2024, Corvus Pharmaceuticals Debt Ratio quarterly data regression had r-value of (0.79) and coefficient of variation of  99.54. View All Fundamentals
 
Debt Ratio  
First Reported
2010-12-31
Previous Quarter
0.03016267
Current Value
0.0593
Quarterly Volatility
0.08781992
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Corvus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Corvus Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 143.4 K, Interest Expense of 864.5 K or Selling General Administrative of 8.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.29. Corvus financial statements analysis is a perfect complement when working with Corvus Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Corvus Pharmaceuticals Correlation against competitors.
For more information on how to buy Corvus Stock please use our How to Invest in Corvus Pharmaceuticals guide.

Latest Corvus Pharmaceuticals' Debt Ratio Growth Pattern

Below is the plot of the Debt Ratio of Corvus Pharmaceuticals over the last few years. It is Corvus Pharmaceuticals' Debt Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Corvus Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Debt Ratio10 Years Trend
Slightly volatile
   Debt Ratio   
       Timeline  

Corvus Debt Ratio Regression Statistics

Arithmetic Mean0.09
Geometric Mean0.05
Coefficient Of Variation99.54
Mean Deviation0.08
Median0.03
Standard Deviation0.09
Sample Variance0.01
Range0.1931
R-Value(0.79)
Mean Square Error0
R-Squared0.63
Significance0.0004
Slope(0.02)
Total Sum of Squares0.11

Corvus Debt Ratio History

2024 0.0593
2023 0.0302
2022 0.0201
2021 0.0238
2020 0.0144
2015 0.0276

Other Fundumenentals of Corvus Pharmaceuticals

Corvus Pharmaceuticals Debt Ratio component correlations

0.790.770.76-0.71-0.430.75-0.150.170.93-0.160.210.460.030.640.20.00.080.04
0.790.990.83-0.76-0.560.68-0.28-0.470.670.280.330.6-0.060.790.09-0.120.19-0.09
0.770.990.87-0.74-0.610.68-0.33-0.490.640.290.410.66-0.120.840.0-0.190.28-0.19
0.760.830.87-0.43-0.870.85-0.62-0.230.55-0.020.630.81-0.250.96-0.33-0.520.51-0.48
-0.71-0.76-0.74-0.430.01-0.36-0.190.22-0.78-0.380.09-0.13-0.05-0.32-0.49-0.410.14-0.24
-0.43-0.56-0.61-0.870.01-0.640.860.26-0.140.19-0.88-0.840.19-0.910.570.78-0.780.75
0.750.680.680.85-0.36-0.64-0.49-0.010.59-0.130.290.52-0.370.77-0.2-0.370.13-0.16
-0.15-0.28-0.33-0.62-0.190.86-0.490.210.170.35-0.8-0.590.25-0.680.480.77-0.760.66
0.17-0.47-0.49-0.230.220.26-0.010.210.25-0.68-0.22-0.30.1-0.350.110.17-0.180.18
0.930.670.640.55-0.78-0.140.590.170.250.03-0.040.270.10.420.360.31-0.160.24
-0.160.280.29-0.02-0.380.19-0.130.35-0.680.03-0.240.03-0.20.020.10.35-0.250.14
0.210.330.410.630.09-0.880.29-0.8-0.22-0.04-0.240.810.070.75-0.56-0.710.95-0.8
0.460.60.660.81-0.13-0.840.52-0.59-0.30.270.030.81-0.020.85-0.58-0.630.74-0.64
0.03-0.06-0.12-0.25-0.050.19-0.370.250.10.1-0.20.07-0.02-0.170.360.340.040.2
0.640.790.840.96-0.32-0.910.77-0.68-0.350.420.020.750.85-0.17-0.36-0.550.58-0.51
0.20.090.0-0.33-0.490.57-0.20.480.110.360.1-0.56-0.580.36-0.360.86-0.620.82
0.0-0.12-0.19-0.52-0.410.78-0.370.770.170.310.35-0.71-0.630.34-0.550.86-0.740.82
0.080.190.280.510.14-0.780.13-0.76-0.18-0.16-0.250.950.740.040.58-0.62-0.74-0.89
0.04-0.09-0.19-0.48-0.240.75-0.160.660.180.240.14-0.8-0.640.2-0.510.820.82-0.89
Click cells to compare fundamentals

About Corvus Pharmaceuticals Financial Statements

Corvus Pharmaceuticals shareholders use historical fundamental indicators, such as Debt Ratio, to determine how well the company is positioned to perform in the future. Although Corvus Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Corvus Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Corvus Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Debt Ratio 0.03  0.06 
Cash Flow To Debt Ratio(17.42)(18.29)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Corvus Stock Analysis

When running Corvus Pharmaceuticals' price analysis, check to measure Corvus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corvus Pharmaceuticals is operating at the current time. Most of Corvus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corvus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corvus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corvus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.